A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
Price : $35 *
At a glance
- Drugs Emiplacel (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 08 Dec 2015 According to a Pluristem Therapeutics Inc. media release, the company announced positive data from 1 cohort of PLX-PAD used for the treatment of Pulmonary Arterial Hypertension.